PAS
CRNX icon

Park Avenue Securities’s Crinetics Pharmaceuticals CRNX Stock Holding History

Park Avenue Securities’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
5,941
-1,111
-16% -$41.3K ﹤0.01% 1679
2026
Q1 		$256K Buy
7,052
+12
+0.2% +$536 ﹤0.01% 1374
2025
Q4 		$328K Buy
+7,040
New +$313K ﹤0.01% 1280

Other funds holding CRNX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return

Park Avenue Securities's CRNX Position: Q2 2026 in Review

Park Avenue Securities reduced its Crinetics Pharmaceuticals (CRNX) stake by 16% in Q2 2026, selling an estimated $41.3K and leaving 5,941 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Park Avenue Securities first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $328K in Q4 2025. 52 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Park Avenue Securities held 5,941 shares of Crinetics Pharmaceuticals worth $222K as of Q2 2026.
  • Park Avenue Securities sold 1,111 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $41.3K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1679 holding.
  • Park Avenue Securities first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Park Avenue Securities's Crinetics Pharmaceuticals position peaked at $328K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.